Abstract
INTRODUCTION
Crohn's disease (CD), an idiopathic chronic infla mmatory disease, is a form of inflammatory bowel disease (IBD) and primarily affects the gastrointestinal tract. This disease causes the development of ulcers and complications, including abscesses and fistulas, affecting all layers of the intestinal wall [1, 2] . It is reported that CD has an annual incidence of approximately 24 per 100000 in Europe and 19 per 100000 in North America. However, the incidence rate of CD is still increasing in developing countries, particularly in China due to its considerable increase in gross domestic product (GDP) [3, 4] and improvement in quality of life [5] . MicroRNAs (miRNAs) are small endogenous RNAs that can degrade targeted mRNA or inhibit protein synthesis, and increasing evidence shows that miRNAs play a key role in regulating the intestinal immune system [69] . For example, miR29b inhibits transforming growth factorβ (TGFβ)-induced intestinal fibrosis, and let-7 regulates the activity of nuclear factor-κB (NF-κB) and mediates interleukin (IL)-6 down-regulation in CD patients [10, 11] . Furthermore, miR192, miR142 3p, and miR21 are notably upregulated in paediatric IBD patients [12] , whereas miR4955p and miR19b are downregulated in the inflamed bowel of CD patients [13, 14] . miRNA125 (miR125) family, an miRNA family highly conserved throughout evolution, consists of miR125a and miR125b [15] . It has been shown that miR125a inhibits innate macrophage responses by suppressing macrophage differentiation, and the expression level of miR125a is downregulated in systemic lupus erythematosus (SLE) [16, 17] . miR125b was correlated with rheumatoid arthritis (RA) disease activity and may serve as a potential biomarker for treatment response in early RA [18] . To date, few studies have investigated the impact of dysregulated miR 125a/b expression in CD patients. Therefore, the aim of this study was to determine the association of circulating miR125a/b expression with the risk and disease severity of CD and with inflammatory cytokines.
MATERIALS AND METHODS

Participants
Twentynine clinically active CD (ACD) patients and 37 patients with CD in clinical remission (RCD) were enrolled in this study from May 2014 to June 2016 at the Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology. The diagnosis of CD was determined according to the Lennard-Jones criteria [19] , and active clinical disease was defined as Crohn's disease activity index (CDAI) above 150 points. Patients with the following conditions were excluded: arthritis with complications or other au toimmune diseases; history of malignant tumour or complications; severe renal and/or kidney dysfunction; and history of serious surgery or severe infection. In the meantime, 37 healthy controls (HCs) age and gendermatched to the CD patients were enrolled. The study was approved by the Ethics Committee of The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, and all participants provided written informed consent.
Sample collection and total RNA extraction
Blood samples were collected from all participants into EDTA tubes when they were enrolled in this study and after a 3mo treatment in the case of ACD patients. After collection, the blood samples were centrifuged at 1000 g for 15 mins at 4 ℃; then, the supernatant (plasma) was removed and stored at 80 ℃ for further analysis. If red blood cell lysis was discovered, a repeat blood sample was collected from patients or HCs. Total RNA was extracted from the samples with TRIzol reagent (Invitrogen, CA, United States) according to the manufacturer's instructions.
miR-125a/b determination by qPCR
Total RNA was reverse transcribed using the PrimerScript Realtime Reagent kit (TAKARA BIO Inc. Shiga, Japan). Subsequently, miR125 a/b expression levels were quantitated with SYBR Premix Ex TaqTM II (TAKARA BIO Inc., Shiga, Japan). The expression level of miR125a/b was calculated using the 2 ΔΔt method and U6 was used as the internal reference.
IL-17, TNF-α, and IFN-γ measurement by ELISA
The measurement of IL-17, tumour necrosis factor (TNFα), and interferon (IFN-γ) levels in plasma samples from ACD and RCD patients (but not HCs) was performed using commercial enzymelinked immunosorbent assay (ELISA) kits, according to the manufacturer's instructions (all purchased from eBioscience, CA, United States).
Disease evaluation and treatment of A-CD patients
Creaction protein (CRP), erythrocyte sedimentation rate (ESR), and Crohn's disease activity index (CDAI) were used to assess the severity of CD. In ACD patients, effective treatments, including immunosuppressive agents and biologics, among others, were used, according to disease status and clinical experience. After 3mo treatment, the CDAI and blood of patients were assessed again, and changes in miR125a/b expression were analysed based on clinical remission achievement. the Wilcoxon signedrank test. Receiver operating characteristic (ROC) curve analysis was performed to assess the value of miR125a/b expression in differentiating ACD from RCD patients and patients from HCs. Spearman's test was used to analyse the correlation of miR125a/b expression with disease severity and inflammatory cytokines. P < 0.05 was considered significant.
RESULTS
Characteristics
As shown in Table 1 , the 29 patients of the ACD group had a mean age of 31.38 ± 9.51 years, whereas the 37 patients of the RCD and the 37 HCs had a mean ages of 31.97 ± 8.86 and 31.41 ± 5.69 years, respectively. No difference in age or gender was found between groups (P > 0.05), although significant differences in CRP and ESR (P < 0.001) were observed between groups. Significant differences in inflammatory cytokines IL-17, TNF-α, and IFN and in CDAI were also found between ACD and RCD patients (P < 0.001).
miR-125a/b expression in A-CD patients, R-CD patients, and HCs
Plasma miR125a expression was decreased in ACD Figure 1B . Interestingly, diagnostic value was discovered for miR125a in differentiating ACD from RCD patients [area under ROC curve (AUC) = 0.854, 95%CI: 0.7580.949) and patients from HCs (AUC = 0.780, 95%CI: 0.6650.895] (Figure 2A and B) . However, miR125b failed as a predictive factor in differentiating ACD from RCD patients (AUC = 0.571, 95%CI: 0.4230.718) and patients from HCs (AUC = 0.629, 95%CI: 0.4920.766) (Figure 2A and B). Moreover, neither miR125a nor miR125b was able to differentiate RCD patients from HCs (AUC = 0.537, 95%CI: 0.4060.668; AUC = 0.590, 95%CI: 0.4610.720, respectively) ( Figure 2C ).
Correlations of miR-125a/b expression with disease severity in CD patients
Negative correlations of miR125a with CRP (r = 0.439, P = 0.017), ESR (r = 0.412, P = 0.026), and CDAI (r = 0.526, P = 0.003) in ACD patients were observed, as shown in Figure 3AC . However, no association was found between miR125b and CRP, ESR, or CDAI in ACD patients ( Figure 3DF ). Regarding RCD patients, we found that the expression of miR125a was negatively correlated with CRP (r = 0.342, P = 0.038) and CDAI (r = 0.379, P = 0.021), but not ESR (r = 0.140, P = 0.410) ( Figure  4AC ). In RCD patients, miR125b was significantly associated with ESR (r = 0.326, P = 0.049), but not with CRP (r = 0.068, P = 0.691) or CDAI (r = 0.126, P = 0.457) ( Figure 4DF ).
Correlations of miR-125a/b expression with inflammatory cytokines in CD patients
Negative correlations were detected for miR125a with the inflammatory factors IL-17 (r = 0.446, P = 0.015) and TNFα (r = 0.518, P = 0.004), but not with IFN-γ (r = 0.203, P = 0.290), in ACD patients, as shown in Figure 5AC . However, no association of miR125b with the inflammatory factors IL-17 (r = 0.027, P = 0.890), TNFα (r = 0.091, P = 0.640) and IFN-γ (r = 0.198, P = 0.304) was found in ACD patients ( Figure 5DF) . Regarding RCD patients, we observed no correlation of miR125a or miR125b with the inflammatory factors IL-17, TNF-α or IFN-γ, as shown in Figure 6A -F.
miR-125a/b expression in A-CD patients after treatment
After 3mo treatment, 19 of 29 ACD patients achieved clinical remission (CDAI < 150), whereas 10 patients failed to achieve clinical remission. In patients with clinical remission, the miR125a levels dramatically increased compared with the baseline (P = 0.009); conversely, in nonremission patients, miR125a levels remained unchanged compared with the baseline. No changes in miR125b expression were detected, either in remission or nonremission patients after treatment (Figure 7) .
DISCUSSION
CD, a chronic debilitating syndrome, affects all layers of the gastrointestinal tract, causes severe diarrhea, abdominal pain, weight loss, metabolic disorder, and malabsorption, and is a major health concern, leading to huge financial losses of up to $2.2 billion dollars per year in the United States alone [2023] . Although the pathogenesis of CD is still unclear, accumulating evidence shows that environmental factors, genetics, autoimmunity, and dietary habits may contribute to its development and progression [24, 25] . As an important genetic factor, miRNA dysregulation is involved in the aetiological mechanism of several autoimmune diseases, including CD [26] ; however, the role of miR 125a/b expression in CD risk and management is largely unstudied [27] . In this prospective study, we observed three notable findings. First, miR125a expression was decreased in ACD patients compared with RCD patients and HCs. The results also showed the ability of miR125a expression levels to distinguish ACD from RCD patients and from HCs, which was not possible using miR125b expression levels. Second, miR125a was negatively correlated with disease severity in ACD patients, and negative correlations of miR125a with inflammatory cytokines were also found in ACD patients. Third, miR125a levels were dramatically increased in ACD patients who achieved clinical remission after 3mo treatment, whereas miR125a levels remained unchanged in nonremission patients. No changes in miR125b expression were detected in remission or nonremission ACD patients after treatment.
The miR-125a gene is located on chromosome 19 and in a cluster with miR99b and miR7e [28] . In the healthy population, the largest contributor of circulating miR125a may be germinal center (GC) and hematopoietic stem cells (HSCs). Shaham et al suggest that miR125a is enriched in HSCs (up to 23fold more than in total bone marrow), particularly in long term HSCs (up to 6fold). Moreover, miR125a is not restricted to the stem cell population, and its cluster members, miR99b and let7e, are preferentially expressed by centroblasts in the GC [16] . Studies show that miR125a is downregulated in peripheral CD3 + T cells and negatively correlated with RANTES (also known as CCL5 chemokine) expression by targeting the KLF13 gene in SLE patients [17] . Interestingly, miR 125a expression is also decreased in oral lichen planus, which is a Tcellmediated autoimmune disease of the oral mucosa [29] . Furthermore, miR125a is identified as a key regulator of CD4 + Tcell differentiation that prevents autoimmune pathogenesis by controlling the balance between tolerance and autoimmunity [30] . Recently, it was reported that miR125a participates in immune thrombocytopenic purpura (ITP), by modulating Tregs and Th17 [31] , which play a key role in CD development and progression and are correlated with CD disease activity [3234] . These studies indicate that miR125a is an antiinflammatory gene that plays a key role in regulating autoimmune diseases, which is consistent with our results showing that miR125a expression is decreased in ACD patients and may be used to differentiate ACD from RCD patients and from HCs. This might be due to the anti inflammatory effect of miR125a, because the levels of inflammatory cytokines were markedly increased in ACD patients compared with those of RCD patients and HCs, whereas the extent of inflammation in RCD patients was similar to that of HCs. The results showing a negative correlation between miR125a and the inflammatory cytokines IL-17 and TNF-α further confirmed this point of view.
In addition, we found a negative association of miR 125a with disease severity in ACD patients. Partly in line with our results, Murata et al [35] reported that miR125a was negatively correlated with some indices of disease activity including CRP in RA, and reduced levels of miR125a were associated with severe trauma through inflammatory cytokine IL-10 regulation, as shown in polytrauma patients [36] , most likely, because of the powerful antiinflammatory effect of miR125a. Thus, miR125a was able to predict the disease severity of CD. Furthermore, we found that the miR125a levels were dramatically increased in ACD patients who achieved clinical remission after 3mo treatment, whereas they remained unchanged in patients who failed to achieve remission. The results proved once again that miR-125a is closely related to inflammation and might be a therapeutic target for CD in the future. Figure 7 miR-125a/b expression in active Crohn's disease patients after treatment. After 3-mo treatment, miR-125a expression was increased in A-CD patients who achieved clinical remission but remained stable in patients who failed to achieve remission. Conversely, no changes in miR-125b expression were observed in either remission or non-remission patients after 3-mo treatment. Comparison between visits in the same group was performed by the Wilcoxon signed-rank test. P < 0.05 was considered significant. A-CD: Active Crohn's disease.
miR125b has been shown to target the 3' un translated region of the TNF-α gene to negatively regulate the inflammatory response [37] . However, another study has shown that miR125b could promote macrophage mediated inflammation by increasing the expression of costimulatory factor [38] . These studies suggest that miR125b has both anti and pro inflammatory effects. We found no correlation of miR125b with inflammatory factors in A-CD patients, and miR125b was not able to differentiate ACD from RCD patients and from HCs, most likely because miR 125b has both anti and proinflammatory effects, which has been reported in previous studies. Thus, the role of miR-125b in regulating inflammation in CD remains unclear [16, 39, 40] . Then, we analysed the target genes of miR125a and miR125b by Validated Target Module-MicroRNA-gene analysis using the software miRWalk 2.0 [41] , which showed that miR125a had 234 reported target genes, whereas miR125b had 391 reported target genes, and that they shared 110 target genes. Conversely, most miR125a and miR 125b target genes were different, which may explain the differences between miR125a and miR125b in CD.
To the best of our knowledge, this was the first study investigating the correlation between circulating miR 125a/b expression and the risk and disease severity of CD and with inflammatory cytokines. Notwithstanding, there were still some limitations in our study. First, we did not detect the expression of miR125a/b in the intestinal tract, where miRNA dysregulation might be more frequent than in blood. However, it is difficult to obtain normal intestinal tract tissue from HCs and CD patients who remain remission. Second, the sample size of our study was relatively small, and a larger sample is needed for further studies. Third, IL-17, TNFα, and IFN-γ expression was not detected in HCs in this study, which would help to further elucidate the role of miR-125a/b in inflammation, which we will investigate in future studies. Finally, the levels of Tregs and Th17 cells, which are essential for CD development and progression, were not determined in the present study. We will also assess these levels in future studies.
In summary, circulating miR125a but not miR125b is decreased in active disease status and negatively correlates with disease severity and inflammatory cytokines in patients with Crohn's disease. Therefore, this study sheds some light on the measurement of circulating miR125a for the diagnosis and treatment of CD patients.
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Background
Crohn's disease (CD), an idiopathic chronic inflammatory disease, is a form of inflammatory bowel diseases (IBD) and primarily affects the gastrointestinal tract. Few studies have investigated the impact of dysregulated miR-125a/b expression in CD patients.
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Crohn's disease activity index (CDAI) was used to differentiate A-CD from R-CD patients. Patients with a CDAI above 150 points were defined as A-CD patients, and those with a CDAI below 150 points were defined as R-CD patients.
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